News
EQS-Adhoc: Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
EQS-Adhoc: Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
EQS-Adhoc: Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
EQS-Adhoc: Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil
EQS-Adhoc: Relief Therapeutics Announces Executive Changes
EQS-Adhoc: Relief Therapeutics Announces Executive Changes
EQS-Adhoc: Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir
EQS-Adhoc: Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir
EQS-Adhoc: Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence
EQS-Adhoc: Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil